UBS Group’s HCA Healthcare HCA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$305M Sell
643,482
-462,294
-42% -$233M 0.05% 420
2025
Q4
$516M Sell
1,105,776
-496,823
-31% -$231M 0.08% 226
2025
Q3
$683M Buy
1,602,599
+38,317
+2% +$14.9M 0.11% 176
2025
Q2
$599M Buy
1,564,282
+456,114
+41% +$164M 0.1% 191
2025
Q1
$383M Buy
1,108,168
+94,993
+9% +$30.6M 0.07% 279
2024
Q4
$304M Buy
1,013,175
+543,849
+116% +$190M 0.06% 325
2024
Q3
$191M Buy
469,326
+63,201
+16% +$23.1M 0.04% 437
2024
Q2
$130M Sell
406,125
-156
-0% -$50.7K 0.03% 516
2024
Q1
$136M Buy
406,281
+55,545
+16% +$17M 0.03% 505
2023
Q4
$94.9M Buy
350,736
+4,709
+1% +$1.16M 0.03% 592
2023
Q3
$85.1M Buy
346,027
+35,033
+11% +$9.59M 0.03% 568
2023
Q2
$94.4M Buy
310,994
+59,793
+24% +$16.6M 0.03% 522
2023
Q1
$66.2M Buy
251,201
+43,210
+21% +$11M 0.02% 642
2022
Q4
$49.9M Buy
207,991
+73,614
+55% +$16.5M 0.02% 802
2022
Q3
$24.7M Sell
134,377
-80,011
-37% -$15.9M 0.01% 1130
2022
Q2
$36M Sell
214,388
-25,001
-10% -$5.37M 0.01% 936
2022
Q1
$60M Sell
239,389
-116,928
-33% -$29.4M 0.02% 755
2021
Q4
$91.5M Buy
356,317
+11,819
+3% +$2.89M 0.03% 643
2021
Q3
$83.6M Buy
344,498
+23,200
+7% +$5.67M 0.03% 602
2021
Q2
$66.4M Sell
321,298
-19,416
-6% -$3.96M 0.02% 693
2021
Q1
$64.2M Buy
340,714
+66,808
+24% +$11.8M 0.02% 697
2020
Q4
$45M Buy
273,906
+74,715
+38% +$10.9M 0.02% 837
2020
Q3
$24.8M Sell
199,191
-334,394
-63% -$41.4M 0.01% 1033
2020
Q2
$51.8M Buy
533,585
+243,972
+84% +$25.4M 0.02% 586
2020
Q1
$26M Sell
289,613
-137,097
-32% -$17.8M 0.01% 848
2019
Q4
$63.1M Sell
426,710
-14,323
-3% -$1.92M 0.02% 639
2019
Q3
$53.1M Buy
441,033
+116,820
+36% +$15.1M 0.02% 665
2019
Q2
$43.8M Buy
324,213
+57,216
+21% +$7.23M 0.02% 731
2019
Q1
$34.8M Buy
266,997
+70,715
+36% +$9.5M 0.01% 828
2018
Q4
$24.4M Sell
196,282
-81,020
-29% -$10.9M 0.01% 953
2018
Q3
$38.6M Buy
277,302
+38,089
+16% +$4.74M 0.02% 809
2018
Q2
$24.5M Buy
239,213
+112,007
+88% +$11.3M 0.01% 1039
2018
Q1
$12.3M Sell
127,206
-23,216
-15% -$2.25M 0.01% 1521
2017
Q4
$13.2M Sell
150,422
-61,576
-29% -$4.95M 0.01% 1509
2017
Q3
$16.9M Sell
211,998
-133,475
-39% -$10.7M 0.01% 1218
2017
Q2
$30.1M Buy
345,473
+38,045
+12% +$3.22M 0.02% 819
2017
Q1
$27.4M Buy
307,428
+36,579
+14% +$3.05M 0.01% 840
2016
Q4
$20M Sell
270,849
-44,823
-14% -$3.36M 0.01% 1025
2016
Q3
$23.9M Sell
315,672
-6,834
-2% -$523K 0.01% 873
2016
Q2
$24.8M Sell
322,506
-9,267
-3% -$732K 0.02% 814
2016
Q1
$25.9M Sell
331,773
-9,130
-3% -$638K 0.02% 734
2015
Q4
$23.1M Sell
340,903
-28,895
-8% -$2.02M 0.02% 869
2015
Q3
$28.6M Sell
369,798
-4,349
-1% -$385K 0.02% 703
2015
Q2
$33.9M Sell
374,147
-127,800
-25% -$10.2M 0.02% 683
2015
Q1
$37.8M Buy
501,947
+26,931
+6% +$1.93M 0.03% 617
2014
Q4
$34.9M Buy
+475,016
New +$33.4M 0.02% 691

Other funds holding HCA

UBS Group's HCA Position: Q1 2026 in Review

UBS Group reduced its HCA Healthcare (HCA) stake by 42% in Q1 2026, selling an estimated $233M and leaving 643,482 shares worth $305M. The position accounts for 0.05% of the portfolio, ranked #420.

UBS Group first reported a position in HCA in Q4 2014 and has held it in 46 quarters since. The position peaked at $683M in Q3 2025. 1,415 funds tracked by Wall St. Rank hold HCA as of Q1 2026.

  • UBS Group held 643,482 shares of HCA Healthcare worth $305M as of Q1 2026.
  • UBS Group sold 462,294 HCA Healthcare shares in Q1 2026, an estimated $233M.
  • HCA Healthcare made up 0.05% of UBS Group's portfolio in Q1 2026, its #420 holding.
  • UBS Group first reported a position in HCA Healthcare in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's HCA Healthcare position peaked at $683M in Q3 2025.
  • 1,415 funds tracked by Wall St. Rank held HCA Healthcare as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.